A comprehensive update on the pharmacological management of heterotopic ossification following hip arthroplasty: a level I evidenced based expert opinion

References

• Beckmann JT, Wylie JD, Kapron AL, et al. The effect of NSAID prophylaxis and operative variables on heterotopic ossification after hip arthroscopy. Am J Sports Med. 2014 June 01;42(6):1359–1364.
   PubMedGoogle Scholar
• Hamid N, Ashraf N, Bosse MJ, et al. Radiation therapy for heterotopic ossification prophylaxis acutely after elbow trauma: a prospective randomized study. The Journal of Bone and Joint Surgery. American Volume. 2010;92(11):2032–2038.
   PubMedGoogle Scholar
• Griffin SM, Sims SH, Karunakar MA, et al. Heterotopic ossification rates after acetabular fracture surgery are unchanged without indomethacin prophylaxis. Clinical Orthopaedics and Related Research. 2013;471(9):2776–2782.
   PubMedGoogle Scholar
• Guo JJ, Tang N, Yang HL, et al. Impact of surgical approach on postoperative heterotopic ossification and avascular necrosis in femoral head fractures: a systematic review. Int Orthop. 2010 March 01;34(3):319–322.
   PubMedGoogle Scholar
• Ahrengart L. Periarticular heterotopic ossification after total hip arthroplasty. risk factors and consequences. Clin Orthop Relat Res. 1991 Feb;263:49–58.
   Google Scholar
• Ahrengart L, Lindgren U. Heterotopic bone after hip arthroplasty. defining the patient at risk. Clin Orthop Relat Res. 1993 Aug;293:153–159.
   Google Scholar
• Eggli S, Woo A. Risk factors for heterotopic ossification in total hip arthroplasty. Arch Orthop Trauma Surg. 2001 Oct;121(9):531–535.
   PubMedGoogle Scholar
• Neal B, Gray H, MacMahon S, et al. Incidence of heterotopic bone formation after major hip surgery. ANZ J Surg. 2002 Nov;72(11):808–821.
   PubMed Web of Science ®Google Scholar
• Macfarlane RJ, Han Ng B, Gamie Z, et al. Pharmacological treatment of heterotopic ossification following hip and acetabular surgery. Expert Opin Pharmacother. 2008 April 01;9(5):767–786.
   PubMed Web of Science ®Google Scholar
• Brunnekreef JJ, Hoogervorst P, Ploegmakers MJ, et al. Is etoricoxib effective in preventing heterotopic ossification after primary total hip arthroplasty? Int Orthop. 2013 April 01;37(4):583–587.
   PubMedGoogle Scholar
• Neal B. Effects of heterotopic bone formation on outcome after hip arthroplasty. ANZ J Surg. 2003 Jun;73(6):422–426.
   PubMedGoogle Scholar
• Neal BC, Rodgers A, Clark T, et al. A systematic survey of 13 randomized trials of non-steroidal anti-inflammatory drugs for the prevention of heterotopic bone formation after major hip surgery. Acta Orthop Scand. 2000 January 01;71(2):122–128.
   PubMed Web of Science ®Google Scholar
• Pellegrini VD Jr., Gregoritch SJ. Preoperative irradiation for prevention of heterotopic ossification following total hip arthroplasty. J Bone Joint Surg Am. 1996 Jun;78(6):870–881.
   PubMedGoogle Scholar
• Kienapfel H, Koller M, Wüst A, et al. Prevention of heterotopic bone formation after total hip arthroplasty: a prospective randomised study comparing postoperative radiation therapy with indomethacin medication. Arch Orthop Trauma Surg. 1999;119(5–6):296–302.
   PubMedGoogle Scholar
• Coventry MB, Scanlon PW. The use of radiation to discourage ectopic bone. A nine-year study in surgery about the Hip. J Bone Joint Surg Am. 1981 Feb;63(2):201–208.
   PubMed Web of Science ®Google Scholar
• Gieringer M, Gosepath J, Naim R. Radiotherapy and wound healing: principles, management and prospects (review). Oncol Rep. 2011 Aug;26(2):299–307.
   PubMedGoogle Scholar
• Grohs JG, Schmidt M, Wanivenhaus A. Selective COX-2 inhibitor versus indomethacin for the prevention of heterotopic ossification after hip replacement: a double-blind randomized trial of 100 patients with 1-year follow-up. Acta Orthop. 2007 Feb;78(1):95–98.
   PubMed Web of Science ®Google Scholar
• Kan S-L, Yang B, Ning G-Z, et al. Nonsteroidal Anti-inflammatory drugs as prophylaxis for heterotopic ossification after total hip arthroplasty: a systematic review and Meta-Analysis. Medicine. 2015;94(18):e828.
   PubMedGoogle Scholar
• Kjaersgaard-Andersen P, Schmidt SA. Indomethacin for prevention of ectopic ossification after hip arthroplasty. Acta Orthop Scand. 1986 Feb;57(1):12–14.
   PubMed Web of Science ®Google Scholar
• Knelles D, Barthel T, Karrer A, et al. Prevention of heterotopic ossification after total hip replacement. A prospective, randomised study using acetylsalicylic acid, indomethacin and fractional or single-dose irradiation. J Bone Joint Surg Br. 1997 Jul;79(4):596–602.
   PubMedGoogle Scholar
• Oni JK, Pinero JR, Saltzman BM, et al. Effect of a selective COX-2 inhibitor, celecoxib, on heterotopic ossification after total hip arthroplasty: a case-controlled study. Hip Int J Clin Exp Res Hip Pathol Ther. 2014 May-Jun;24(3):256–262.
   PubMedGoogle Scholar
• Saudan M, Saudan P, Perneger T, et al. Celecoxib versus ibuprofen in the prevention of heterotopic ossification following total hip replacement: a prospective randomised trial. J Bone Joint Surg Br. 2007 Feb;89(2):155–159.
   PubMedGoogle Scholar
• van der Heide Hj, Rijnberg WJ, Van Sorge A, et al. Similar effects of rofecoxib and indomethacin on the incidence of heterotopic ossification after hip arthroplasty. Acta Orthop. 2007 Feb;78(1):90–94.
   PubMedGoogle Scholar
• Vielpeau C, Joubert JM, Hulet C. Naproxen in the prevention of heterotopic ossification after total hip replacement. Clin Orthop Relat Res. 1999 Dec;369:279–288.
   Google Scholar
• Winkler S, Springorum HR, Vaitl T, et al. Comparative clinical study of the prophylaxis of heterotopic ossifications after total hip arthroplasty using etoricoxib or diclofenac. Int Orthop. 2016 Apr;40(4):673–680.
   PubMedGoogle Scholar
• CI HJ, Glasziou P, Greenhalgh T, et al. 2011. Oxford CEBM levels of evidence. Oxford Centre for Evidence-Based Medicine. [cited 2022 Jan]. Available at https://wwwcebmnet/indexaspx?o=5653.
   Google Scholar
• van der Heide Hj, Koorevaar RCT, Lemmens RC, et al. Rofecoxib inhibits heterotopic ossification after total hip arthroplasty. Arch Orthop Trauma Surg. 2007 Sep;127(7):557–561.
   PubMedGoogle Scholar
• Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021 Mar 29;372:n71.
   PubMedGoogle Scholar
• Brooker AF, Bowerman JW, Robinson RA, et al. Ectopic ossification following total hip replacement. Incidence and a method of classification. J Bone Joint Surg Am. 1973 Dec;55(8):1629–1632.
   PubMed Web of Science ®Google Scholar
• Dorn U, Grethen C, Effenberger H, et al. Indomethacin for prevention of heterotopic ossification after hip arthroplasty. A randomized comparison between 4 and 8 days of treatment. Acta Orthop Scand. 1998 Apr;69(2):107–110.
   PubMed Web of Science ®Google Scholar
• Elmstedt E, Lindholm TS, Nilsson OS, et al. Effect of ibuprofen on heterotopic ossification after hip replacement. Acta Orthop Scand. 1985 Feb;56(1):25–27.
   PubMed Web of Science ®Google Scholar
• Gebuhr P, Soelberg M, Orsnes T, et al. Naproxen prevention of heterotopic ossification after hip arthroplasty. A prospective control study of 55 patients. Acta Orthop Scand. 1991 Jun;62(3):226–229.
   PubMed Web of Science ®Google Scholar
• Günal I, Hazer B, Seber S, et al. Prevention of heterotopic ossification after total hip replacement: a prospective comparison of indomethacin and salmon calcitonin in 60 patients. Acta Orthop Scand. 2001 November 01;72:467–469.
   PubMed Web of Science ®Google Scholar
• Kolbl O, Knelles D, Barthel T, et al. Randomized trial comparing early postoperative irradiation vs. the use of nonsteroidal antiinflammatory drugs for prevention of heterotopic ossification following prosthetic total hip replacement. Int J Radiat Oncol Biol Phys. 1997 Dec 1;39(5):961–966.
   PubMedGoogle Scholar
• Persson PE, Sodemann B, Nilsson OS. Preventive effects of ibuprofen on periarticular heterotopic ossification after total hip arthroplasty. A randomized double-blind prospective study of treatment time. Acta Orthop Scand. 1998 Apr;69(2):111–115.
   PubMed Web of Science ®Google Scholar
• Reis HJ, Kusswetter W, Schellinger T. The suppression of heterotopic ossification after total hip arthroplasty. Int Orthop. 1992;16(2):140–145.
   PubMed Web of Science ®Google Scholar
• Sell S, Phillips O, Handel M. No difference between two doses of diclofenac in prophylaxis of heterotopic ossifications after total hip arthroplasty. Acta Orthop Scand. 2004 Feb;75(1):45–49.
   PubMed Web of Science ®Google Scholar
• Schmidt SA, Kjaersgaard-Andersen P, Pedersen NW, et al. The use of indomethacin to prevent the formation of heterotopic bone after total hip replacement. A randomized, double-blind clinical trial. J Bone Joint Surg Am. 1988 Jul;70(6):834–838.
   PubMed Web of Science ®Google Scholar
• Wahlstrom O, Risto O, Djerf K, et al. Heterotopic bone formation prevented by diclofenac. prospective study of 100 hip arthroplasties. Acta Orthop Scand. 1991 Oct;62(5):419–421.
   PubMed Web of Science ®Google Scholar
• Pohl F, Seufert J, Tauscher A, et al. The influence of heterotopic ossification on functional status of hip joint following total hip arthroplasty. Strahlentherapie und Onkologie: Organ der Deutschen Rontgengesellschaft. 2005 Aug;181(8):529–533.
   PubMedGoogle Scholar
• Kölbl O, Knelles D, Barthel T, et al. Preoperative irradiation versus the use of nonsteroidal anti-inflammatory drugs for prevention of heterotopic ossification following total hip replacement: the results of a randomized trial. Int J Radiat Oncol Biol Phys. 1998 Sep 1;42(2):397–401.
   PubMedGoogle Scholar
• Almasbakk K, Roysland P, editors. DOES INDOMETHACIN (IMC) PREVENT POSTOPERATIVE ECTOPIC OSSIFICATION IN TOTAL HIP-REPLACEMENT. Acta Orthop Scand. 1977. SCANDINAVIAN UNIVERSITY PRESS PO BOX 2959 TOYEN, JOURNAL DIVISION CUSTOMER.
   Google Scholar
• Cella JP, Salvati EA, Sculco TP. Indomethacin for the prevention of heterotopic ossification following total hip arthroplasty. effectiveness, contraindications, and adverse effects. J Arthroplasty. 1988;3(3):229–234.
   PubMedGoogle Scholar
• Ritter MA, Gioe TJ. The effect of indomethacin on para-articular ectopic ossification following total hip arthroplasty. Clin Orthop Relat Res. 1982 Jul;167:113–117.
   Google Scholar
• Romanò CL, Duci D, Romanò D, et al. Celecoxib versus indomethacin in the prevention of heterotopic ossification after total hip arthroplasty. J Arthroplasty. 2004 Jan;19(1):14–18.
   PubMedGoogle Scholar
• Saudan M, Saudan P, Perneger T, et al. Celecoxib versus ibuprofen in the prevention of heterotopic ossification following total hip replacement: a prospective randomised trial. The Journal of Bone and Joint Surgery. British Volume. 2007;89(2):155–159.
   PubMedGoogle Scholar
• Ghlichloo I, Gerriets V. Nonsteroidal Anti-inflammatory drugs (NSAIDs). statPearls. Treasure Island (FL):StatPearls Publishing;2022. Copyright © 2022.
   Google Scholar
• van der Heide Hj, Spruit M, Slappendel R, et al. Prophylaxis for heterotopic ossification after primary total hip arthroplasty. A cohort study between indomethacin and meloxicam. Acta Orthop Belg. 2004 Jun;70(3):240–246.
   PubMedGoogle Scholar
• Laine L. Gastrointestinal effects of NSAIDs and coxibs. J Pain Symptom Manage. 2003 February 01;25(2, Supplement):32–40.
   Google Scholar
• Singh G, Goldstein J, Bensen W, et al. OP0053 success-1 in osteoarthritis (oa) trial: celecoxib significantly reduces risk of serious upper gi complications compared to NSAIDs while providing similar efficacy in 13,274 randomised patients. Ann of the Rheum Dis. 2001;60:A165.
   Google Scholar
• Chan FKL, Wong VWS, Suen BY, et al. Combination of a cyclo-oxygenase-2 inhibitor and a proton-pump inhibitor for prevention of recurrent ulcer bleeding in patients at very high risk: a double-blind, randomised trial. Lancet (London, England). 2007;369(9573):1621–1626.
   PubMed Web of Science ®Google Scholar
• Lai LH, FKJCoig C. Nonsteroid anti-inflammatory drug-induced gastroduodenal injury. Current Opinion in Gastroenterology. 2009;25(6):544–548.
   PubMedGoogle Scholar
• Moodley I. Review of the cardiovascular safety of COXIBs compared to NSAIDS. Cardiovasc J Afr. 2008 Mar-Apr;19(2):102–107.
   PubMedGoogle Scholar
• Jones P, RJCdi L. Oral Cyclo-Oxygenase 2 Inhibitors versus other oral analgesics for acute soft tissue injury. Clinical Drug Investigation. 2010;30(7):419–437.
   PubMedGoogle Scholar
• Ahrengart L, Blomgren G, Törnkvist H. Short-term ibuprofen to prevent ossification after hip arthroplasty. no effects in a prospective randomized study of 47 arthrosis cases. Acta Orthop Scand. 1994 Apr;65(2):139–141.
   PubMed Web of Science ®Google Scholar
• Fransen M, Anderson C, Douglas J, et al. Safety and efficacy of routine postoperative ibuprofen for pain and disability related to ectopic bone formation after Hip replacement surgery (HIPAID): randomised controlled trial. BMJ. 2006 Sep 9 333(7567):519.
   PubMedGoogle Scholar
• Lavernia CJ, Contreras JS, Villa JM, et al. Celecoxib and heterotopic bone formation after total hip arthroplasty. J Arthroplasty. 2014 Feb;29(2):390–392.
   PubMedGoogle Scholar
• Barbato M, D’Angelo E, Di Loreto G, et al. Adherence to routine use of pharmacological prophylaxis of heterotopic ossification after total hip arthroplasty: results from an Italian multicenter, prospective, observational survey. J Orthop Traumatol. 2012 June 01;13(2):63–67.
   PubMedGoogle Scholar
• Xue D, Zheng Q, Li H, et al. Selective COX-2 inhibitor versus nonselective COX-1 and COX-2 inhibitor in the prevention of heterotopic ossification after total hip arthroplasty: a meta-analysis of randomised trials. Int Orthop. 2011 Jan;35(1):3–8.
   PubMedGoogle Scholar
• Neal BC, Rodgers A, Gray H, et al. No effect of low-dose aspirin for the prevention of heterotopic bone formation after total hip replacement: a randomized trial of 2,649 patients. Acta Orthop Scand. 2000 January 01;71(2):129–134.
   PubMed Web of Science ®Google Scholar
• Gebuhr P, Sletgård J, Dalsgård J, et al. Heterotopic ossification after hip arthroplasty:A randomized double-blind multicenter study of tenoxicam in 147 hips. Acta Orthop Scand. 1996 January 01;67(1):29–32.
   PubMed Web of Science ®Google Scholar
• Legenstein R, Bösch P, Ungersböck A. Indomethacin versus meloxicam for prevention of heterotopic ossification after total hip arthroplasty. Arch Orthop Trauma Surg. 2003 April 01;123(2):91–94.
   PubMedGoogle Scholar
• Barthel T, Baumann B, Nöth U, et al. Prophylaxis of heterotopic ossification after total hip arthroplasty: a prospective randomized study comparing indomethacin and meloxicam. Acta Orthop Scand. 2002 Dec;73(6):611–614.
   PubMed Web of Science ®Google Scholar
• Zhu X-T, Chen L, Lin J-H. Selective COX-2 inhibitor versus non-selective COX-2 inhibitor for the prevention of heterotopic ossification after total hip arthroplasty: a meta-analysis. Medicine. 2018;97(31):e11649.
   PubMedGoogle Scholar
• Grohs JG, Schmidt M, Wanivenhaus A. Selective COX-2 inhibitor versus indomethacin for the prevention of heterotopic ossification after hip replacement: a double-blind randomized trial of 100 patients with 1-year follow-up. Acta Orthop. 2007 January 01;78(1):95–98.
   PubMed Web of Science ®Google Scholar
• Vazquez SR. Drug-drug interactions in an era of multiple anticoagulants: a focus on clinically relevant drug interactions. Hematol Am Soc Hematol Educ Program.2018 Nov 30; 2018(1):339–347.
   PubMedGoogle Scholar
• Di Minno A, Frigerio B, Spadarella G, et al. Old and new oral anticoagulants: food, herbal medicines and drug interactions. Blood Rev. 2017 July 01;31(4):193–203.
   PubMed Web of Science ®Google Scholar
• Yong JW, Yang LX, Ohene BE, et al. Periprocedural heparin bridging in patients receiving oral anticoagulation: a systematic review and meta-analysis. BMC Cardiovasc Disord. 2017 Dec 13 17(1):295.
   PubMedGoogle Scholar
• Agency EM. New safety advice for diclofenac: new measures AIM to minimise cardiovascular risks. 2013.
   Google Scholar
• Yibirin M, De Oliveira D, Valera R, et al. Adverse effects associated with proton pump inhibitor use. Cureus.2021 Jan 18 13(1):e12759.
   PubMedGoogle Scholar
• Fossmark R, Martinsen TC, Waldum HL. Adverse effects of proton pump inhibitors-Evidence and plausibility. Int J Mol Sci.2019 Oct 21; 20(20):5203.
   Google Scholar
• Gwee KA, Goh V, Lima G, et al. Coprescribing proton-pump inhibitors with nonsteroidal anti-inflammatory drugs: risks versus benefits. J Pain Res. 2018;11:361–374.
   PubMed Web of Science ®Google Scholar
• Regula J, Butruk E, Dekkers CP, et al. Prevention of NSAID-associated gastrointestinal lesions: a comparison study pantoprazole versus omeprazole. Am J Gastroenterol. 2006 Aug;101(8):1747–1755.
   PubMed Web of Science ®Google Scholar
• Klotz U. Proton pump inhibitors–their pharmacological impact on the clinical management of acid-related disorders. Arzneimittelforschung. 2009;59(6):271–282.
   PubMedGoogle Scholar
• Moreira Dias L. Pantoprazole: a proton pump inhibitor. Clin Drug Investig. 2009;29 Suppl 2:3–12.
   PubMedGoogle Scholar
• Cheer SM, Prakash A, Faulds D, et al. Pantoprazole: an update of its pharmacological properties and therapeutic use in the management of acid-related disorders. Drugs. 2003;63(1):101–133.
   PubMedGoogle Scholar
• Matheson AJ, Jarvis B. Lansoprazole: an update of its place in the management of acid-related disorders. Drugs. 2001;61(12):1801–1833.
   PubMedGoogle Scholar
• Scheiman JM. The use of proton pump inhibitors in treating and preventing NSAID-induced mucosal damage. Arthritis Res Ther. 2013;15(Suppl 3):S5.
   PubMedGoogle Scholar
• Zhao WG, Liu L, Li XL, et al. Celecoxib prevents against heterotopic ossification after total hip arthroplasty. J Clin Rehabilitative Tissue Eng Res. 2011;15. 9760–9763.
   Google Scholar
• Burssens A, Thiery J, Kohl P, et al. Prevention of heterotopic ossification with tenoxicam following total hip arthroplasty: a double-blind, placebo-controlled dose-finding study. Acta Orthop Belg. 1995;61(3):205–211.
   PubMedGoogle Scholar
• Neal BC, Rodgers A, Gray H, et al. No effect of low-dose aspirin for the prevention of heterotopic bone formation after total hip replacement: a randomized trial of 2,649 patients. Acta Orthop Scand. 2000 Apr;71(2):129–134.
   PubMed Web of Science ®Google Scholar